Access to HIV/AIDS Medicines in Exchanges (2014)

Prescription medicines are a crucial component of treatment for HIV/AIDS. Multidrug regimens have substantially reduced HIV progression to AIDS, opportunistic infections, hospitalizations, and deaths. Even so, early ART regimens often required patients to ingest several large pills multiple times per day. New formulations, such as single-tablet regimens, reduced the pill burden dramatically, improving adherence and slowing disease progression. This fact sheet offers insight into access to these medicines in the new health insurance exchanges.

Access to Diabetes Medicines in Exchanges (2014)

The annual number of patients who were newly diagnosed with diabetes has tripled in the past twenty years, and type 2 diabetes accounts for 95% of diagnosed diabetes in adults. As many previously uninsured people enroll in exchange coverage and access primary care, the diagnosed cases of diabetes may increase further. Medicines are a key component of managing diabetes. Most patients take oral medicines to stabilize blood sugar levels, but over time, many patients also add insulin to their treatment regimens.

Access to Asthma Medicines in Exchanges (2014)

Asthma is a common, chronic lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. Asthma affects people of all ages, but it most often starts during childhood. In the United States, more than 25 million people are known to have asthma, including about 7 million children. Goals of asthma treatment are reduced impairment from symptoms; minimized risk of asthma attacks and other adverse outcomes, such as hospitalizations and loss of lung function; and minimized side effects of asthma medicines.

Restricting Access to Medicines At the Expense of Patients Warrants a Candid Conversation

06.23.14 | By

It has become increasingly clear in recent weeks that far too many patients simply cannot access innovative medicines that help treat costly chronic diseases. While more Americans now have health care coverage under the Affordable Care Act (ACA), they still face insurmountable barriers to access that hinder our collective efforts to prevent, manage, and cure these conditions.

Investments in Innovation, Jobs, and Economic Development

06.20.14 | By

Innovation is the engine of economic growth and development.  Research and development (R&D) spending is what creates jobs and makes innovation a reality.  As the global economy continues to recover and regain its former strength, the pharmaceutical industry remains the world’s largest source of R&D spending.  According to a recent article in the

Week in Review: The Importance of Patient Perspectives

06.20.14 | By

“The biopharmaceutical industry’s top priority is to provide patients with access to innovative, life-saving medicines.”

Over 3 Million Dollars Available for Young Scientists

06.19.14 | By

For nearly 50 years the PhRMA Foundation has helped thousands of scientists advance their careers and has inspired new generations to enter biopharmaceutical research. The early-career support provided by the PhRMA Foundation has been a catalyst for scientists to become leaders in their organizations and fields. Their programs help build a larger pool of highly-trained researchers to meet the growing needs of academic institutions, the government and the research-intensive pharmaceutical industry. Are you one of them?

Understanding Health Insurance Exchanges State-by-State

06.19.14 | By

It’s no secret that when it comes to the Affordable Care Act, health insurance exchange coverage varies depending on where you live. From the plans offered, to premiums, to the type of Marketplace, not every state looks alike.

That’s why we created state-by-state fact sheets on health insurance exchange coverage and access to prescription medicines across the country.

First Technology Pilot Program Shares Perspective of Sickle Cell Disease Community with FDA

06.18.14 | By

In the guest blog below, Michele Lloyd-Puryear, Special Consultant to Genetic Alliance, discusses key findings from a patient-driven data collection effort intended to complement the Food and Drug Administration’s (FDA) patient-focused drug development initiative which was part of the most recent reauthorization of the Prescription Drug User Fee Act.

More than 430 Medicines in Development to Treat Chronic Diseases Affecting Older Americans

06.18.14 | By

Aging is a fact of life but the good news is that life expectancy continues to climb and more and more Americans are living fuller, richer lives thanks in large part to innovative medicines being developed by biopharmaceutical companies. As the baby boomer generation reaches retirement age, the demands on our health care system will continue to rise due to the increasing prevalence of chronic diseases affecting seniors.


Subscribe to RSS - Opinion